臨床整形外科46巻6号

2011年06月発行

境界領域/知っておきたい

悪性骨・軟部腫瘍におけるホウ素中性子捕捉療法（BNCT）

著者： 藤本卓也¹ 鈴木実² 市川秀喜³

所属機関： ¹兵庫県立がんセンター整形外科 ²京都大学原子炉実験所 ³神戸学院大学薬学部

ページ範囲：P.534 - P.541

はじめに

　近年の科学技術の発展は，悪性腫瘍に対する診断・治療技術にも様々な恩恵をもたらしている．優れた抗腫瘍効果を示す重粒子線などの粒子線による放射線療法もそのひとつであり，手術による切除が治療の基本となっている悪性骨・軟部腫瘍では，身体深部に発生した腫瘍を非侵襲的に加療できる唯一の手段となっている．また，複数の抗癌剤を用いた系統的な化学療法に加え，最近では腫瘍細胞に特異的に作用する分子標的治療薬を導入するなど悪性骨・軟部腫瘍の治療方法にはめざましい進歩がある．実際の臨床現場では腫瘍の発生部位とその組織学的特徴に応じて，これら3つの手術，放射線，および化学療法を駆使して治療が行われる．しかし，治療開始時にすでに遠隔転移を認める症例や，骨盤などの体幹部に発生した手術的に切除困難な腫瘍については，いまだ有効な治療法がなく予後も悪いため，さらなる新たな治療方法が求められているのが現状である．

参考文献

1) Locher GL:Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther 36:1-13, 1936

2) Coderre JA, Morris GM:The radiation biology of boron neutron capture therapy. Radiat Res 151:1-18, 1999

3) Carlson J, Sjoberg S, Larson BS:Present status of boron neutron capture therapy. Acta Oncol 31:803-813, 1992

4) Slatkin DN:A history of boron neutron capture therapy of brain tumors. Postulation of a brain radiation dose tolerance limit. Brain 114:1609-1629, 1991

5) Hatanaka H, Nakagawa Y:Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys 28:1061-1066, 1994

6) Snyder HR, Reedy AH, Lennarz W:Synthesis of aromatic boronic acids. Aldehyde boric acids and a boronic acid analog of tyrosine. J Am Chem Soc 80:835-838, 1958

7) Mishima Y, Ichihashi M, Hatta S, et al:New thermal neutron capture therapy for malignant melanoma:melanogenesis-seeking 10B molecule-melanoma cell interaction from in vitro to first clinical trial. Pigment Cell Res 2:226-234, 1989

8) Ichikawa H, Taniguchi E, Fujimoto T, et al:Biodistribution of BPA and BSH after single, repeated and simultaneous administration for neutron-capture therapy of cancer. Appl Radiat Isot 67:S111-114, 2009

9) Fukuda H, Hiratsuka J, Kobayashi T, et al:Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med 26:97-103, 2003

10) Kawabata S, Miyatake S, Kuroiwa T:Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res (Tokyo) 50:51-60, 2009

11) Kato I, Ono K, Sakurai Y, et al:Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 61:1069-1073, 2004

12) Suzuki M, Sakurai Y, Hagiwara S, et al:First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn J Clin Oncol 37:376-381, 2007

13) Suzuki M, Sakurai Y, Masunaga S, et al:A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity. Jpn J Clin Oncol 37:245-249, 2007

14) Tanaka H, Sakurai Y, Suzuki M, et al:Experimental demonstration of beam characteristics for cyclotron-based epithermal neutron source (C-BENS). Proceedings 14th International Congress on Neutron Capture Therapy. Buenos Aires, Argentina, 2010

15) Mishima Y:Molecular and biological control of melanogenesis through tyrosinase genes, and intrinsic and extrinsic regulatory factors. Pigment Cell Res 7:376-387, 1994

16) Papaspyrou M, Frinendegen LE, Gartner HM:Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res 54:6311-6314, 1994

17) Gabel D, Preusse D, Haritz D, et al:Pharmacokinetics of BSH in patients with malignant brain tumours as prerequisite for a Phase I clinical trial of boron neutron capture. Acta Neurochir (Wien) 139:606-611, 1997

18) Kawabata S, Miyatake S, Kajimoto Y, et al:The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases. J Neurooncol 65:159-165, 2003

19) Ono K, Masunaga S, Kinashi Y, et al:Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors:its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys 34:1081-1086, 1996

20) Ono K, Masunaga S, Suzuki M, et al:The combined effect of boronophenylalanine and borocaptate in boron neutron capture therapy for SCCVII tumors in mice. Int J Radiat Oncol Biol Phys 43:431-436, 1999

21) Imahori Y, Ueda S, Ohmori Y, et al:Position emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas:part II. Clin Cancer Res 4:1833-1841, 1998

22) Barth RF, Coderre JA, Vicente MG, et al:Boron neutron capture therapy of cancer:current status and future prospects. Clin Cancer Res 11:3987-4002, 2005

23) Takeuchi A:Possible application of boron neutron capture therapy to canine osteosarcoma. Jpn J Vet Sci 47:869-878, 1985

24) Lemmen P, Weissfloch L, Auberger T, et al:Uptake and distribution of the boron-containing ether lipid B-Et-11-OMe in tumor-bearing mice. Anticancer Drugs 6:744-748, 1995

25) Weissfloch L, Bremer M, Lemmen P, et al:New drugs for BNCT:an experimental approach. Strahlenther Onkol 175:118-120, 1999

26) Tjarks W, Barth RF, Rotaru JH, et al:In vivo evaluation of phosphorous-containing derivatives of dodecahydro-closo-dodecaborate for boron neutron capture therapy of gliomas and sarcomas. Anticancer Res 21:841-846, 2001

27) Mitin VN, Kulakov VN, Khokhlov VF, et al:Comparison of BNCT and GdNCT efficacy in treatment of canine cancer. Appl Radiat Isot 67:S299-301, 2009

28) Ferrari C, Zonta C, Cansolino L, et al:Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy. Appl Radiat Isot 67:S341-344, 2009

29) Altieri S, Ballarini F, Bortolussi S, et al:BNCT of Osteosarcoma:a new research project at Pavia reactor. Proceedings 14th International Congress on Neutron Capture Therapy. Buenos Aires, Argentina, 2010

30) Gregoire V, Begg AC, Huiskamp R, et al:Selectivity of boron carriers for boron neutron capture therapy:pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. Radiother Oncol 27:46-54, 1993

31) Yamada Y, Toda K, Kahl SB, et al:Enhanced therapeutic effect on murine melanoma and angiosarcoma cells by boron neutron capture therapy using a boronated metalloporphyrin. Kobe J Med Sci 40:25-37, 1994

32) Pignol JP, Oudart H, Chauvel P, et al:Selective delivery of 10B to soft tissue sarcoma using 10B-L-borophenylalanine for boron neutron capture therapy. Br J Radiol 71:320-323, 1998

33) Fujimoto T, Ichikawa H, Akisue T, et al:Accumulation of MRI contrast agents in malignant fibrous histiocytoma for gadolinium neutron capture therapy. Appl Radiat Isot 67:S355-358, 2009

34) Fujimoto T, Andoh T, Sudo T, et al:Evaluation of BPA uptake in clear cell sarcoma (CCS) in vitro and development of an in vivo model of CCS for BNCT studies. Appl Radiat Isot, in press.

35) Andoh T, Fujimoto T, Sudo T, et al:Boron neutron capture therapy for clear cell sarcoma (CCS):Biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models. Appl Radiat Isot, in press.

36) Kato I, Fujita Y, Maruhashi A, et al:Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 67:S37-42, 2009